Several advanced cancer treatments are noted for achieving durable responses. Immunotherapies, such as checkpoint inhibitors, have shown remarkable durability in certain cancers like melanoma and non-small cell lung cancer. Targeted therapies, which hone in on specific genetic mutations in tumors, also offer durable responses, particularly in cancers such as chronic myeloid leukemia.
